PubRank

Robert D Cardiff

Author PubWeight™ 195.05‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 2005 5.81
2 MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004 5.61
3 Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 2009 5.31
4 PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell 2003 5.13
5 Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 2004 5.13
6 Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood 2002 4.88
7 Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell 2002 4.36
8 Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell 2006 4.15
9 Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell 2005 3.68
10 Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci U S A 2003 3.61
11 Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. Cancer Res 2004 3.43
12 Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-origin model for prostate cancer heterogeneity. Nat Cell Biol 2013 2.90
13 Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci U S A 2002 2.89
14 Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. Cancer Res 2004 2.84
15 Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression. Proc Natl Acad Sci U S A 2007 2.64
16 Syngeneic mouse mammary carcinoma cell lines: two closely related cell lines with divergent metastatic behavior. Clin Exp Metastasis 2005 2.52
17 Prostatic intraepithelial neoplasia in genetically engineered mice. Am J Pathol 2002 2.48
18 Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer 2007 2.41
19 Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. Cancer Res 2002 2.29
20 Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev 2003 2.27
21 Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors. Am J Pathol 2002 2.26
22 Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol 2007 2.23
23 Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Res 2003 2.11
24 Developmental context determines latency of MYC-induced tumorigenesis. PLoS Biol 2004 2.05
25 Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci U S A 2009 2.01
26 Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer Cell 2010 1.88
27 ShcA signalling is essential for tumour progression in mouse models of human breast cancer. EMBO J 2008 1.82
28 Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol 2008 1.74
29 Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis. Cancer Res 2004 1.67
30 Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res 2013 1.66
31 Enhanced in vivo bioluminescence imaging using liposomal luciferin delivery system. J Control Release 2009 1.60
32 Maternal dioxin exposure combined with a diet high in fat increases mammary cancer incidence in mice. Environ Health Perspect 2010 1.60
33 Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer. Cancer Res 2008 1.59
34 PPAR gamma signaling exacerbates mammary gland tumor development. Genes Dev 2004 1.58
35 STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas. Breast Cancer Res 2012 1.56
36 T-cadherin supports angiogenesis and adiponectin association with the vasculature in a mouse mammary tumor model. Cancer Res 2008 1.54
37 Effects of FVB/NJ and C57Bl/6J strain backgrounds on mammary tumor phenotype in inducible nitric oxide synthase deficient mice. Transgenic Res 2007 1.54
38 SLITs suppress tumor growth in vivo by silencing Sdf1/Cxcr4 within breast epithelium. Cancer Res 2008 1.52
39 Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors. Cancer Res 2011 1.52
40 E mu-BRD2 transgenic mice develop B-cell lymphoma and leukemia. Blood 2003 1.51
41 Kinase-inactive glycogen synthase kinase 3beta promotes Wnt signaling and mammary tumorigenesis. Cancer Res 2005 1.50
42 EMT tumorigenesis in the mouse mammary gland. Lab Invest 2007 1.47
43 A critical role for p27kip1 gene dosage in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci U S A 2004 1.47
44 Activation of beta -catenin signaling in differentiated mammary secretory cells induces transdifferentiation into epidermis and squamous metaplasias. Proc Natl Acad Sci U S A 2002 1.44
45 ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2. Cancer Res 2010 1.43
46 Activation of different Wnt/beta-catenin signaling components in mammary epithelium induces transdifferentiation and the formation of pilar tumors. Oncogene 2002 1.43
47 Ets2-dependent stromal regulation of mouse mammary tumors. Mol Cell Biol 2003 1.43
48 Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ. Clin Cancer Res 2006 1.39
49 Activation of beta-catenin in prostate epithelium induces hyperplasias and squamous transdifferentiation. Oncogene 2003 1.37
50 In vivo positron-emission tomography imaging of progression and transformation in a mouse model of mammary neoplasia. Proc Natl Acad Sci U S A 2004 1.37
51 Mouse mammary tumor virus c-rel transgenic mice develop mammary tumors. Mol Cell Biol 2003 1.36
52 Tumor escape in a Wnt1-dependent mouse breast cancer model is enabled by p19Arf/p53 pathway lesions but not p16 Ink4a loss. J Clin Invest 2008 1.36
53 Oncogenic signaling pathways activated in DMBA-induced mouse mammary tumors. Toxicol Pathol 2005 1.34
54 Polyomavirus middle T-induced mammary intraepithelial neoplasia outgrowths: single origin, divergent evolution, and multiple outcomes. Mol Cancer Ther 2004 1.33
55 From whence will they come? - A perspective on the acute shortage of pathologists in biomedical research. J Vet Diagn Invest 2007 1.32
56 HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. Cancer Res 2005 1.32
57 Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth. Cancer Res 2006 1.30
58 pRb inactivation in mammary cells reveals common mechanisms for tumor initiation and progression in divergent epithelia. PLoS Biol 2004 1.27
59 Molecular analysis of metastasis in a polyomavirus middle T mouse model: the role of osteopontin. Breast Cancer Res 2004 1.27
60 ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer. Proc Natl Acad Sci U S A 2013 1.26
61 Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential. Proc Natl Acad Sci U S A 2009 1.26
62 Impaired DNA replication within progenitor cell pools promotes leukemogenesis. PLoS Biol 2005 1.25
63 Do-it-yourself (DIY) pathology. Nat Biotechnol 2008 1.23
64 Spontaneous pituitary abnormalities and mammary hyperplasia in FVB/NCr mice: implications for mouse modeling. Comp Med 2003 1.22
65 Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model. Cancer Res 2012 1.20
66 B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer. Cancer Res 2012 1.15
67 Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer. Proc Natl Acad Sci U S A 2013 1.14
68 Gene expression profiling of neu-induced mammary tumors from transgenic mice reveals genetic and morphological similarities to ErbB2-expressing human breast cancers. Cancer Res 2003 1.13
69 Molecular characterization of the transition to malignancy in a genetically engineered mouse-based model of ductal carcinoma in situ. Mol Cancer Res 2004 1.13
70 Ultrasound increases nanoparticle delivery by reducing intratumoral pressure and increasing transport in epithelial and epithelial-mesenchymal transition tumors. Cancer Res 2012 1.12
71 Angiogenic acceleration of Neu induced mammary tumor progression and metastasis. Cancer Res 2004 1.12
72 The aryl hydrocarbon receptor inhibits prostate carcinogenesis in TRAMP mice. Carcinogenesis 2006 1.12
73 Inflammation and atrophy precede prostatic neoplasia in a PhIP-induced rat model. Neoplasia 2006 1.11
74 Advancing translational research. Science 2011 1.11
75 Adiponectin deficiency limits tumor vascularization in the MMTV-PyV-mT mouse model of mammary cancer. Clin Cancer Res 2009 1.11
76 The Snf1-related kinase, Hunk, is essential for mammary tumor metastasis. Proc Natl Acad Sci U S A 2009 1.10
77 Deregulation of Stat5 expression and activation causes mammary tumors in transgenic mice. Int J Cancer 2004 1.10
78 Heterogeneous tumor evolution initiated by loss of pRb function in a preclinical prostate cancer model. Cancer Res 2005 1.10
79 PTEN deficiency in a luminal ErbB-2 mouse model results in dramatic acceleration of mammary tumorigenesis and metastasis. J Biol Chem 2009 1.09
80 Fibroblast growth factor receptor signaling dramatically accelerates tumorigenesis and enhances oncoprotein translation in the mouse mammary tumor virus-Wnt-1 mouse model of breast cancer. Cancer Res 2010 1.07
81 Mammary carcinoma behavior is programmed in the precancer stem cell. Breast Cancer Res 2008 1.07
82 Distinct ErbB-2 coupled signaling pathways promote mammary tumors with unique pathologic and transcriptional profiles. Cancer Res 2007 1.06
83 Persistent mammary hyperplasia in FVB/N mice. Comp Med 2003 1.03
84 An open environment CT-US fusion for tissue segmentation during interventional guidance. PLoS One 2011 1.02
85 Prostatic intraepithelial neoplasia in mice with conditional disruption of the retinoid X receptor alpha allele in the prostate epithelium. Cancer Res 2002 1.02
86 Mammary tumor latency is increased in mice lacking the inducible nitric oxide synthase. Int J Cancer 2003 1.02
87 Phosphatase and tensin homologue deleted on chromosome 10 deficiency accelerates tumor induction in a mouse model of ErbB-2 mammary tumorigenesis. Cancer Res 2008 1.01
88 Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ. Breast Cancer Res 2005 0.98
89 Heterogeneity of mammary lesions represent molecular differences. BMC Cancer 2006 0.98
90 Copper-doxorubicin as a nanoparticle cargo retains efficacy with minimal toxicity. Mol Pharm 2010 0.97
91 Preclinical imaging of mammary intraepithelial neoplasia with positron emission tomography. J Mammary Gland Biol Neoplasia 2006 0.97
92 Prostatic intraepithelial neoplasia and intestinal metaplasia in prostates of probasin-RAS transgenic mice. Prostate 2004 0.95
93 Longitudinal investigation of permeability and distribution of macromolecules in mouse malignant transformation using PET. Clin Cancer Res 2010 0.94
94 Hypoxia-inducible factor-1 facilitates cervical cancer progression in human papillomavirus type 16 transgenic mice. Am J Pathol 2007 0.94
95 Pathologists needed to cope with mutant mice. Nature 2007 0.94
96 Tumor promotion by caspase-resistant retinoblastoma protein. Proc Natl Acad Sci U S A 2005 0.94
97 The PIAS-like protein Zimp10 is essential for embryonic viability and proper vascular development. Mol Cell Biol 2007 0.93
98 Fibroblast growth factor 8 isoform B overexpression in prostate epithelium: a new mouse model for prostatic intraepithelial neoplasia. Cancer Res 2002 0.93
99 Hunk is required for HER2/neu-induced mammary tumorigenesis. J Clin Invest 2011 0.91
100 Simultaneous haploinsufficiency of Pten and Trp53 tumor suppressor genes accelerates tumorigenesis in a mouse model of prostate cancer. Differentiation 2008 0.91
101 Early vascular deficits are correlated with delayed mammary tumorigenesis in the MMTV-PyMT transgenic mouse following genetic ablation of the NG2 proteoglycan. Breast Cancer Res 2012 0.89
102 Id-1 is not expressed in the luminal epithelial cells of mammary glands. Breast Cancer Res 2003 0.88
103 The membrane mucin MUC4 is elevated in breast tumor lymph node metastases relative to matched primary tumors and confers aggressive properties to breast cancer cells. Breast Cancer Res 2009 0.87
104 ATG proteins mediate efferocytosis and suppress inflammation in mammary involution. Autophagy 2013 0.87
105 Epidermal growth factor receptor-dependent activation of Gab1 is involved in ErbB-2-mediated mammary tumor progression. Oncogene 2003 0.87
106 Acceleration of mouse mammary tumor virus-induced murine mammary tumorigenesis by a p53 172H transgene: influence of FVB background on tumor latency and identification of novel sites of proviral insertion. Am J Pathol 2002 0.86
107 Evidence for phenotypic plasticity in aggressive triple-negative breast cancer: human biology is recapitulated by a novel model system. PLoS One 2012 0.85
108 Over 60% of NIH extramural funding involves animal-related research. Vet Pathol 2007 0.85
109 Diet-induced metabolic change induces estrogen-independent allometric mammary growth. Proc Natl Acad Sci U S A 2012 0.85
110 Effect of c-neu/ ErbB2 expression levels on estrogen receptor alpha-dependent proliferation in mammary epithelial cells: implications for breast cancer biology. Cancer Res 2006 0.85
111 An integrin binding-defective mutant of insulin-like growth factor-1 (R36E/R37E IGF1) acts as a dominant-negative antagonist of the IGF1 receptor (IGF1R) and suppresses tumorigenesis but still binds to IGF1R. J Biol Chem 2013 0.84
112 Mice expressing SV40 T antigen directed by the intestinal trefoil factor promoter develop tumors resembling human small cell carcinoma of the colon. Mol Cancer Res 2004 0.84
113 Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant. Cancer Res 2006 0.83
114 Epithelial-mesenchymal transition in mouse mammary tumorigenesis. Future Oncol 2009 0.83
115 Tuberous sclerosis complex 1: an epithelial tumor suppressor essential to prevent spontaneous prostate cancer in aged mice. Cancer Res 2010 0.83
116 In vivo imaging of the mammary gland: the shape of things to come. J Mammary Gland Biol Neoplasia 2006 0.82
117 Differential sensitivity of mouse epithelial tissues to the polyomavirus middle T oncogene. Am J Pathol 2006 0.81
118 Male mice not alone in research. Science 2010 0.76
119 At last: classification of human mammary cells elucidates breast cancer origins. J Clin Invest 2014 0.76
120 Mouse models of human cancers (part 3). Comp Med 2004 0.76
121 Mouse models of human cancers (Part 2). Comp Med 2004 0.76
122 The use of mouse models of breast cancer and quantitative image analysis to evaluate hormone receptor antigenicity after microwave-assisted formalin fixation. J Histochem Cytochem 2014 0.75
123 Overexpression of progesterone receptor A isoform in mice leads to endometrial hyperproliferation, hyperplasia and atypia. Mol Hum Reprod 2009 0.75
124 The genomic revolution and endocrine pathology. Endocr Pathol 2008 0.75
125 How to phenotype a mouse. Dis Model Mech 2009 0.75
126 One-health wonders. Interview by R. Scott Nolen. J Am Vet Med Assoc 2008 0.75